Slowing ALS Progression Through Gene Therapy

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged by disease, injured by trauma, or worn by time to normal function. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

In this subseries, we focus specifically on gene therapies. We explore the current treatments and examine the advances poised to transform healthcare. Each article in this collection delves into a different aspect of gene therapy’s role within the larger narrative of Regenerative Medicine. 

Certain breakthroughs in science and medicine shine as beacons of hope, offering new possibilities in the battle against diseases. One such glimmer has emerged for those facing amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, with a gene therapy from Umeå University promising to slow disease progression significantly.

The Backdrop of Hope

Researchers at Umeå University and University Hospital of Northern Sweden have worked tirelessly to find treatments for ALS for over three decades. This progressive neurodegenerative disease affects the nerve cells in the brain and spinal cord. ALS can drastically impair a person’s physical abilities, leading to movement, speech, and breathing difficulties.

Despite the difficulties brought about by the disease’s complexity, they persisted in their search for a cure. Their quest led them to a patient with a highly aggressive form of ALS. During their study with this patient, the researchers made a discovery that could have widespread implications for treating ALS. Although the specifics of the discovery have yet to be revealed to the public, it is evident that this breakthrough could be significant in the fight against this devastating disease.

The Path of Discovery

The study concentrates on a particular patient from southern Sweden who was suffering from a severe form of Amyotrophic Lateral Sclerosis (ALS) caused by a genetic mutation in the SOD1 gene. The mutation in the SOD1 gene causes the misfolding and clumping together of SOD1 protein, which can attack and damage the neurons responsible for motor function, leading to the progression of the disease. The patient’s initial diagnosis was highly pessimistic, with a predicted life expectancy of only 1.5 to 2 years.

However, the study found that an experimental gene therapy that targeted the disease-causing SOD1 protein significantly improved the patient’s treatment. The treatment was meticulously administered every four weeks at a university hospital in Copenhagen, Denmark, where the patient was given a high dose of a virus carrying a gene that could target the mutated SOD1 gene. The gene therapy was designed to deliver a healthy gene capable of producing a normal SOD1 protein, which replaced the mutated one.

It was found that the treatment led to a significant decrease in the levels of the disease-causing SOD1 protein in the patient’s cerebrospinal fluid, which indicated that gene therapy was effective in targeting the root cause of the problem. Furthermore, the patient displayed positive clinical outcome measures, including increased strength and motor function and a halt in the progression of ALS. While more research and testing are necessary to determine the safety and long-term efficacy of the gene therapy, the results of the study provide promising evidence that it could be used as a therapeutic option for patients who have ALS caused by SOD1 mutations.

The Broader Implications

This case study stands as a beacon of hope not just for ALS patients with SOD1 mutations but potentially for others grappling with different ALS forms. While this therapy targets a specific genetic mutation in 2% to 6% of ALS cases, its success paves the way for broader applications and encourages further research into gene-based treatments.

While the Umeå University study offers encouraging prospects, it’s crucial to acknowledge the limitations and the need for continued exploration. This therapy, as of now, does not cure ALS but offers a means to arrest its progression, allowing patients like the one from southern Sweden to maintain a level of normalcy and activity previously deemed impossible.

Looking forward, the scientific community is invigorated by gene therapy’s promise of treating ALS. However, realizing its complete potential calls for comprehensive research spanning various ALS types and understanding the long-term efficacy and safety of such treatments.

A Beacon of Optimism

The success story at Umeå University underscores the potent combination of perseverance, innovation, and the promise of gene therapy in confronting ALS. While challenges lay ahead, the path is now lit with optimism, guiding efforts to turn the tide against this relentless disease.

In reflection, progress embodies more than scientific achievement; it symbolizes hope for countless individuals awaiting breakthroughs in ALS treatment. It’s a poignant reminder of the power of research and dedication in unlocking new horizons for medical science, marking a significant step towards mitigating the impact of one of neurology’s most daunting adversaries.

As we herald this landmark phase in ALS research, it’s essential to remain grounded in the reality of the disease’s complexity and the varied manifestations across patients. Nonetheless, this beacon of hope ignites a collective aspiration among researchers, healthcare professionals, and patients, fueling the pursuit of a future where ALS’s grip on lives is significantly loosened.

To learn more about regenerative medicine, read more stories at

© William A. Haseltine, PhD. All Rights Reserved.